Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Serotonin Syndrome 1Neuroendocrine Tumors 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1

Interventions

pembrolizumab 304Carboplatin 157Nivolumab 154Cisplatin 140Cyclophosphamide 131Paclitaxel 127Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 91Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 76Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61Radiation 60durvalumab 60Lenalidomide 59Pemetrexed 59Taxes 57Prednisone 55Bevacizumab 54fludarabine 54olaparib 53Vincristine 50Cytarabine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Random Allocation × 1 year × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡